Supplements could be the next major sector to benefit from the weight-loss drug boom, Novonesis CEO told CNBC on Monday, as the biosolutions company explores whether microbiome products can help patients on popular GLP-1 medicines.
"We have scientific evidence that [is] going to support the patients [on] GLP-1s feeling better, as a companion during the treatment," CEO Ester Baiget told "Squawk Box Europe," referencing an ongoing study with Novo Nordisk.
GLP-1 medications and dietary supplements, such as those being developed by Novonesis, could play complementary roles in managing obesity and supporting longer-term health, she argued.
While medications can help treat obesity, improving the gut microbiome through nutrition and scientifically backed supplements could support longer-term health, Baiget said.
The microbiome refers to the community of microorganisms, including bacteria, fungi and viruses, that live in or on different parts of the body, particularly in the gut.